Neurocrine Bio. (NBIX) PT Lowered to $140 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $166.07 +0.74%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Join SI Premium – FREE
BMO Capital analyst Evan David Seigerman lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $140.00 (from $145.00) while maintaining a Market Perform rating.
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Raised to $224 at Guggenheim
- Neurocrine Bio. (NBIX) PT Raised to $190 at RBC Capital
- Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
